A 360 view of our new Bay Area facility in the heart of biotech: South San Francisco. Here, we are pushing the limits of science, technology and innovation.
There’s a new addition to the South San Francisco skyline – a brand new research facility equipped with state-of-the-art laboratories and collaborative workspaces.
Today marks the grand opening of our new site in the Bay Area. Here our main focus is on researching, developing and commercializing new medicines to treat cancer. This work is a critical piece of our U.S. operations and global R&D footprint, which spans to more than 20 countries with research and manufacturing sites. It also builds on our expertise and legacy of research in oncology.
The 480,000 square-foot facility will put all our cross-functional experts in the Bay Area under one roof, opening up more opportunities for collaboration and innovation in oncology research and development.
“Today, our scientists and colleagues in South San Francisco are exploring new frontiers in exciting areas – like immuno-oncology, tumor targeting, tumor dependencies and precision medicine – and finding new approaches that we hope will change how we treat cancer and other diseases in the future,” said Tom Hudson, senior vice president of R&D and chief scientific officer, AbbVie.
In addition to the nearly 1,000 full-time employees already employed at our campus, we continue to hire across a wide range of R&D disciplines, including drug discovery research, oncology early development, precision medicine, regulatory affairs, clinical trial management and medical affairs, among many others.
“As we officially launch this new facility, we are showcasing our leadership of being a great place to work in the Bay Area and California, while also helping to create jobs that fuel the biotech industry and the local economy,” said Mo Trikha, vice president and head of oncology early development, Bay Area site head, AbbVie.
Along with bringing internal teams closer together, our new location puts us in close proximity to other life science companies, a number of whom we partner with today. This makes it easier for our dedicated and experienced teams to join forces with outside partners that complement our strengths, capabilities and commitment to oncology.
“One thing we know is that solving some of the toughest challenges in medicine requires bringing together diverse minds and areas of expertise – and proximity makes it easier for us to work together to advance science,” said Trikha.
At our new location, we’re also seizing opportunities to nurture and support the local community and biotech community at-large. Along with fostering STEM initiatives in partnership with California Life Science (CLS), our employees also actively volunteer as mentors to other STEM and community initiatives across the Bay Area. In addition, we have partnerships with leading Bay Area biotech incubators. With one of our partners, MBC Biolabs, we sponsor an annual startup competition to drive and support innovation. The early-stage companies that win are provided use of a lab bench and core facilities at MBC Biolabs for a year, as well as opportunities to engage with our scientific and business leaders.
“We’re creating a place for the best and brightest minds in the industry to reimagine what’s possible for patients. At AbbVie in the Bay Area, our potential is truly limitless,” Trikha concludes.
Name: Ilke Limoncu
Email: [email protected]
Call: +1 (650) 540-6145